Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to MDS or Leukemia from Severe Aplastic Anemia. A report by the MDS subcommittee of the chronic malignancies working party (CMWP) and the severe aplastic anemia working party (WPSAA) | Aplastic Anemia and MDS International Foundation

Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to MDS or Leukemia from Severe Aplastic Anemia. A report by the MDS subcommittee of the chronic malignancies working party (CMWP) and the severe aplastic anemia working party (WPSAA)

Journal Title: 
Biol Blood Marrow Transplant
Author(s): 
Hussein AA, Halkes CM, Socié G, Tichelli A, Borne PA, Schaap MN, Foa R, Ganser A, Dufour C, Bacigalupo A, Locasciulli A, Aljurf M, Peters C, Robin M, van Biezen AA, Volin L, De Witte T, Marsh J, Passweg JR, Kröger N
Primary Author: 
Hussein AA
Original Publication Date: 
Thursday, June 5, 2014

One-hundred and forty patients who had received HSCT for MDS or AML transformation following treatment of severe aplastic anemia (SAA) were identified in the EBMT database. The median age at HSCT was 29 years (1-66). Donors were related in 49% and unrelated in 51% cases. The 5 years probability of relapse and non-relapse mortality was 17% and 41%, respectively. The five-year overall survival was 45 + 9%, better for patients untreated or in remission than in patients with refractory disease. Allogeneic HSCT leads to prolonged survival in close to half of the patients transforming to MDS or AML from SAA.

Bone Marrow Diseases: